학술논문
Frontiers of cardiovascular polypills: From atherosclerosis and beyond.
Document Type
Academic Journal
Author
Gnanenthiran SR; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: sgnanenthiran@georgeinstitute.org.au.; Agarwal A; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States.; Patel A; The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
Source
Publisher: Elsevier Science Publishing Country of Publication: United States NLM ID: 9108337 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2615 (Electronic) Linking ISSN: 10501738 NLM ISO Abbreviation: Trends Cardiovasc Med Subsets: MEDLINE
Subject
Language
English
Abstract
Fixed-dose combination (FDC) therapies (also known as polypills) remain underutilized in clinical practice despite over two decades of evidence from randomized controlled trials demonstrating increased adherence to multidrug therapy, improved cardiovascular disease (CVD) risk factor control, and lower incidence of cardiovascular events. Evidence demonstrates that FDC-based implementation strategies can substantially complement and augment current strategies for CVD risk prevention globally. The next decade is likely to extend the frontier of cardiovascular FDC therapies, particularly given expected advances in FDC manufacturing technology and accessibility. FDC-based anti-hypertensive therapies are emerging as integral components of a pragmatic blood pressure lowering strategy. Cardiovascular FDCs are rapidly approaching its coming of age, transforming from heavily hyped research tools to pragmatic clinical instruments. This review evaluates the current evidence for cardiovascular FDCs, barriers to current use, and potential next generation advances.
(Copyright © 2021. Published by Elsevier Inc.)
(Copyright © 2021. Published by Elsevier Inc.)